TY - JOUR
T1 - Predictive factors of non-treatment and non-persistence to osteoporosis medication after fragility hip fractures at 3 years after discharge
T2 - a multicentre, prospective cohort study in the northern Kyushu district of Japan
AU - Kanahori, Masaya
AU - Matsumoto, Yoshihiro
AU - Fujiwara, Toshifumi
AU - Kimura, Atsushi
AU - Tsutsui, Tomoko
AU - Arisumi, Shinkichi
AU - Oyamada, Akiko
AU - Ohishi, Masanobu
AU - Ikuta, Ko
AU - Tsuchiya, Kuniyoshi
AU - Tayama, Naohisa
AU - Tomari, Shinji
AU - Miyahara, Hisaaki
AU - Mae, Takao
AU - Hara, Toshihiko
AU - Saito, Taichi
AU - Arizono, Takeshi
AU - Kaji, Kozo
AU - Mawatari, Taro
AU - Fujiwara, Masami
AU - Takasaki, Minoru
AU - Shin, Kunichika
AU - Ninomiya, Kenichi
AU - Nakaie, Kazutoshi
AU - Antoku, Yasuaki
AU - Iwamoto, Yukihide
AU - Nakashima, Yasuharu
N1 - Funding Information:
Toshifumi Fujiwara received a research grant from 12th Japan Osteoporosis Foundation for Bone Research.
Funding Information:
We gratefully acknowledge the Medical Information Centre, Kyushu University Hospital, for data management of our registry. In addition, we would like to thank Editage (www.editage.com) for English language editing.
Publisher Copyright:
© 2021, International Osteoporosis Foundation and National Osteoporosis Foundation.
PY - 2021/12
Y1 - 2021/12
N2 - Summary: We examined osteoporosis medication use and factors affecting persistence in 497 patients with fragility hip fractures. Only 25.5% of patients received continuous medication for 3 years, and 44.1% of patients received no treatment. Low Barthel index at discharge was a risk factor for both non-treatment and non-persistence to osteoporosis medication. Purpose: Fragility hip fractures (FHF) caused by osteoporosis decrease the quality of life and worsen life expectancy. Use of osteoporosis medication may be an efficient method in the prevention of secondary FHF. However, previous studies have reported low rates of osteoporosis medication and persistence after FHF. This study aimed to evaluate osteoporosis medication use and factors affecting persistence in patients with FHF in the northern Kyushu area of Japan. Methods: A total of 497 FHF patients aged ≥ 60 years with a 3-year follow-up were included. We prospectively collected data from questionnaires sent every 6 months regarding compliance with osteoporosis medication. We compared baseline characteristics among three groups: no treatment (NT), no persistence (NP), and persistence (P), and conducted multivariable regression models to determine covariates associated with non-treatment (NT vs. NP/P) and non-persistence (NP vs. P). Results: There were 219 (44.1%), 151 (30.4%), and 127 (25.5%) patients in the NT, NP, and P groups, respectively. Factors associated with non-treatment were male sex, chronic kidney disease, no previous osteoporosis treatment, and low Barthel index (BI) at discharge. The only factor associated with non-persistence was a low BI at discharge. Factors associated with a low BI at discharge were male sex, older age, trochanteric fracture, and surgical delay. Conclusion: Low BI at discharge is a risk factor for both non-treatment and non-persistence to osteoporosis medication. Therefore, appropriate interventions to improve BI may result in persistence to osteoporosis medication.
AB - Summary: We examined osteoporosis medication use and factors affecting persistence in 497 patients with fragility hip fractures. Only 25.5% of patients received continuous medication for 3 years, and 44.1% of patients received no treatment. Low Barthel index at discharge was a risk factor for both non-treatment and non-persistence to osteoporosis medication. Purpose: Fragility hip fractures (FHF) caused by osteoporosis decrease the quality of life and worsen life expectancy. Use of osteoporosis medication may be an efficient method in the prevention of secondary FHF. However, previous studies have reported low rates of osteoporosis medication and persistence after FHF. This study aimed to evaluate osteoporosis medication use and factors affecting persistence in patients with FHF in the northern Kyushu area of Japan. Methods: A total of 497 FHF patients aged ≥ 60 years with a 3-year follow-up were included. We prospectively collected data from questionnaires sent every 6 months regarding compliance with osteoporosis medication. We compared baseline characteristics among three groups: no treatment (NT), no persistence (NP), and persistence (P), and conducted multivariable regression models to determine covariates associated with non-treatment (NT vs. NP/P) and non-persistence (NP vs. P). Results: There were 219 (44.1%), 151 (30.4%), and 127 (25.5%) patients in the NT, NP, and P groups, respectively. Factors associated with non-treatment were male sex, chronic kidney disease, no previous osteoporosis treatment, and low Barthel index (BI) at discharge. The only factor associated with non-persistence was a low BI at discharge. Factors associated with a low BI at discharge were male sex, older age, trochanteric fracture, and surgical delay. Conclusion: Low BI at discharge is a risk factor for both non-treatment and non-persistence to osteoporosis medication. Therefore, appropriate interventions to improve BI may result in persistence to osteoporosis medication.
UR - http://www.scopus.com/inward/record.url?scp=85114840725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114840725&partnerID=8YFLogxK
U2 - 10.1007/s11657-021-00988-5
DO - 10.1007/s11657-021-00988-5
M3 - Article
C2 - 34515859
AN - SCOPUS:85114840725
SN - 1862-3522
VL - 16
JO - Archives of Osteoporosis
JF - Archives of Osteoporosis
IS - 1
M1 - 132
ER -
